"We will be open to more disruptive acquisitions, larger acquisitions if they make sense," Soriot told reporters.
But he added: "You have to consider the likelihood of that is lower because I don't think we need a large-scale acquisition to succeed."
Soriot said any deals he struck would complement increased investment in five existing growth areas - the new heart drug Brilinta, emerging markets, diabetes care, respiratory medicine and Japan.
Faced with loss of exclusivity on once best-selling medicines and a thin pipeline of new drugs, AstraZeneca needs to consider bold moves to get back on its feet.
Tomorrow AMRN is sold to AZN